Cited by 379TGF-β signaling in diseasesCancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

The DOI matches its Crossref record; 318 of the 320 references it cites were found in a registry or an index.

Overcoming TGFβ-mediated immune evasion in cancer

Tauriello, Daniele V. F., Sancho, Elena, Batlle, Eduard·2022·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Transforming growth factor-β (TGFβ) signalling controls multiple cell fate decisions during development and tissue homeostasis; hence, dysregulation of this pathway can drive several diseases, including cancer. Here we discuss the influence that TGFβ exerts on the composition and behaviour of different cell populations present in the tumour immune microenvironment, and the context-dependent functions of this cytokine in suppressing or promoting cancer. During homeostasis, TGFβ controls inflammatory responses triggered by exposure to the outside milieu in barrier tissues. Lack of TGFβ exacerbates inflammation, leading to tissue damage and cellular transformation. In contrast, as tumours progress, they leverage TGFβ to drive an unrestrained wound-healing programme in cancer-associated fibroblasts, as well as to suppress the adaptive immune system and the innate immune system. In consonance with this key role in reprogramming the tumour microenvironment, emerging data demonstrate that TGFβ-inhibitory therapies can restore cancer immunity. Indeed, this approach can synergize with other immunotherapies - including immune checkpoint blockade - to unleash robust antitumour immune responses in preclinical cancer models. Despite initial challenges in clinical translation, these findings have sparked the development of multiple therapeutic strategies that inhibit the TGFβ pathway, many of which are currently in clinical evaluation.

Integrity signals

Registry

Crossref · 10.1038/s41568-021-00413-6

Cites

318 of 318 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

Items 201–318 of 318

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
Yoo, C., Oh, D. Y., Choi, H. J., Kudo, M., Ueno, M., Kondo, S., Chen, L.-T., Osada, M., Helwig, C., Dussault, I., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000564 · Cited by 155
Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
Bai, X., Yi, M., Jiao, Y., Chu, Q., & Wu, K. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s224013 · Cited by 153
TGF-β1 Reciprocally Controls Chemotaxis of Human Peripheral Blood Monocyte-Derived Dendritic Cells Via Chemokine Receptors
Sato, K., Kawasaki, H., Nagayama, H., Enomoto, M., Morimoto, C., Tadokoro, K., Juji, T., & Takahashi, T. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2285 · Cited by 152
Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
de Streel, G., Bertrand, C., Chalon, N., Liénart, S., Bricard, O., Lecomte, S., Devreux, J., Gaignage, M., Boeck, G. D., Mariën, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17811-3 · Cited by 151
Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models
Otegbeye, F., Ojo, E. O., Moreton, S. A., Mackowski, N., Lee, D. A., Lima, M. J. G. D., & Wald, D. N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191358 · Cited by 147
Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)
Lacouture, M. E., Morris, J. C., Lawrence, D. P., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Berzofsky, J. A., Hsu, F. J., & Guitart, J. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1653-0 · Cited by 145
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma
Faivre, S. J., Santoro, A., Kelley, R. K., Gane, E. J., Costentin, C. E., Gueorguieva, I., Smith, C. L., Cleverly, A., Lahn, M., Raymond, É., et al. (2019) · Liver International · doi:10.1111/liv.14113 · Cited by 142
Structural determinants of integrin β-subunit specificity for latent TGF-β
Dong, X., Hudson, N. E., Lu, C., & Springer, T. A. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2905 · Cited by 141
Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft.
Bandyopadhyay, A. M., López‐Casillas, F., Malik, S. N., Montiel-Hernández, J. L., Mendoza, V., Yang, J., & Sun, L. (2002) · PubMed · Cited by 140
Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β
Metelli, A., Wu, B. X., Riesenberg, B., Guglietta, S., Huck, J. D., Mills, C., Li, A., Rachidi, S., Krieg, C., Rubinstein, M. P., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay4860 · Cited by 139
TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies
Courau, T., Nehar-Belaid, D., Flórez, L. V., Levacher, B., Vazquez, T., Brimaud, F., Bellier, B., & Klatzmann, D. (2016) · JCI Insight · doi:10.1172/jci.insight.85974 · Cited by 136
Dendritic Cell-Specific Disruption of TGF-β Receptor II Leads to Altered Regulatory T Cell Phenotype and Spontaneous Multiorgan Autoimmunity
Ramalingam, R., Larmonier, C. B., Thurston, R. D., Midura‐Kiela, M. T., Zheng, S. G., Ghishan, F. K., & Kiela, P. R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201029 · Cited by 135
Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion
Burkly, L. C., Olson, D., Shapiro, R., Winkler, G., Rosa, J. J., Thomas, D. W., Williams, C., & Chisholm, P. M. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.5.1779 · Cited by 133
The glioblastoma‐derived T‐cell suppressor factor/transforming growth factor beta 2 inhibits the generation of lymphokineactivated killer (LAK) cells
Kuppner, M. C., Hamou, M., Bodmer, S., Fontana, A., & de Tribolet, N. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420416 · Cited by 133
T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
Donkor, M. K., Sarkar, A., Savage, P. A., Franklin, R. A., Johnson, L. K., Jungbluth, A. A., Allison, J. P., & Li, M. O. (2011) · Immunity · doi:10.1016/j.immuni.2011.04.019 · Cited by 130
Transforming growth factor β: a master regulator of the gut microbiota and immune cell interactions
Bauché, D., & Marie, J. C. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.9 · Cited by 130
Preferential Expression of Integrin αvβ8 Promotes Generation of Regulatory T Cells by Mouse CD103+ Dendritic Cells
Païdassi, H., Acharya, M., Zhang, A., Mukhopadhyay, S., Kwon, M., Chow, C., Stuart, L. M., Savill, J., & Lacy‐Hulbert, A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.076 · Cited by 127
TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer
Principe, D. R., Park, A. J., Dorman, M. J., Kumar, S., Viswakarma, N., Rubin, J., Torres, C., McKinney, R. D., Munshi, H. G., Grippo, P. J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0850 · Cited by 125
Human monocytes and macrophages regulate immune tolerance via integrin αvβ8–mediated TGFβ activation
Kelly, A., Gunaltay, S., McEntee, C. P., Shuttleworth, E. E., Smedley, C., Houston, S. A., Fenton, T. M., Levison, S., Mann, E. R., & Travis, M. A. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171491 · Cited by 124
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
Rocconi, R. P., Grosen, E. A., Ghamande, S. A., Chan, J. K., Barve, M. A., Oh, J., Tewari, D. S., Morris, P. C., Stevens, E., Bottsford-Miller, J. N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30533-7 · Cited by 124
Breast cancer‐derived transforming growth factor‐β and tumor necrosis factor‐α compromise interferon‐α production by tumor‐associated plasmacytoid dendritic cells
Sisirak, V., Vey, N., Goutagny, N., Renaudineau, S., Malfroy, M., Thys, S., Treilleux, I., Labidi‐Galy, S. I., Bachelot, T., Dezutter‐Dambuyant, C., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28072 · Cited by 123
Role of TGF-β Signaling in Generation of CD39+CD73+ Myeloid Cells in Tumors
Ryzhov, S. V., Pickup, M. W., Chytil, A., Gorska, A. E., Zhang, Q., Owens, P., Feoktistov, I., Moses, H. L., & Novitskiy, S. V. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400578 · Cited by 123
Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells
Zhong, Z., Carroll, K. D., Policarpio, D., Osborn, C., Gregory, M., Bassi, R., Jimenez, X., Prewett, M., Liebisch, G., Persaud, K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1634 · Cited by 123
TGF-beta attenuates the class II transactivator and reveals an accessory pathway of IFN-γ action
Nandan, D., & Reiner, N. E. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1095 · Cited by 121
Controlling Immunity and Inflammation through Integrin-Dependent Regulation of TGF-β
Nolte, M. A., & Margadant, C. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.10.002 · Cited by 121
Transforming Growth Factor β-Mediated Suppression of Antitumor T Cells Requires FoxP1 Transcription Factor Expression
Stephen, T. L., Rutkowski, M. R., Allegrezza, M. J., Perales‐Puchalt, A., Tesone, A. J., Svoronos, N., Nguyen, J. M., Sarmin, F., Borowsky, M. E., Tchou, J. C., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.08.012 · Cited by 120
Integrin αvβ8–expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells
Takasaka, N., Seed, R. I., Cormier, A., Bondesson, A. J., Lou, J., Elattma, A., Ito, S., Yanagisawa, H., Hashimoto, M., Ma, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122591 · Cited by 119
Correction: Corrigendum: Contribution of classical end-joining to PTEN inactivation in p53-mediated glioblastoma formation and drug-resistant survival
Kang, Y., Balter, B. B., Csizmadia, E., Haas, B. J., Sharma, H., Bronson, R. T., & Yan, C. T. (2017) · Nature Communications · doi:10.1038/ncomms15795 · Cited by 119
TGF‐β1 production by CD4+CD25+ regulatory T cells is not essential for suppression of intestinal inflammation
Kullberg, M. C., Hay, V., Cheever, A. W., Mamura, M., Sher, A., Letterio, J. J., Shevach, E. M., & Piccirillo, C. A. (2005) · European Journal of Immunology · doi:10.1002/eji.200526106 · Cited by 118
Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGFβ inhibitor sequencing in melanoma
Zhao, F., Evans, K., Xiao, C., DeVito, N., Theivanthiran, B., Holtzhausen, A., Siska, P. J., Blobe, G. C., & Hanks, B. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0086 · Cited by 117
The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy
Reader, C. S., Vallath, S., Steele, C. W., Haider, S., Brentnall, A. R., Desai, A., Moore, K. M., Jamieson, N. B., Chang, D. K.-F., Bailey, P. J., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5320 · Cited by 116
Integrin-Mediated TGFβ Activation Modulates the Tumour Microenvironment
Brown, N. F., & Marshall, J. F. (2019) · Cancers · doi:10.3390/cancers11091221 · Cited by 116
Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation
Papaspyridonos, M., Matei, I. R., Huang, Y., André, M. D. R., Brazier, H., Waite, J. C., Chan, A., Kalter, J., Ramos, I., Wu, Q., et al. (2015) · Nature Communications · doi:10.1038/ncomms7840 · Cited by 115
Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer
Lu, W., Yu, W., He, J., Liu, W., Yang, J., Lin, X., Zhang, Y., Wang, X., Jiang, W., Luo, J., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012798 · Cited by 112
TGFβ Signaling Intersects with CD103 Integrin Signaling to Promote T-Lymphocyte Accumulation and Antitumor Activity in the Lung Tumor Microenvironment
Boutet, M., Gauthier, L., Leclerc, M., Gros, G., de Montpréville, V., Théret, N., Donnadieu, E., & Mami‐Chouaib, F. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1545 · Cited by 111
Surface Expression of TGFβ Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer
Metelli, A., Wu, B. X., Fugle, C. W., Rachidi, S., Sun, S., Zhang, Y., Wu, J. D., Tomlinson, S., Howe, P. H., Yang, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1456 · Cited by 111
Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8
Stockis, J., Liénart, S., Colau, D., Collignon, A., Nishimura, S. L., Sheppard, D., Coulie, P. G., & Lucas, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710680114 · Cited by 111
Smad2 Positively Regulates the Generation of Th17 Cells*
Martínez, G., Zhang, Z., Reynolds, J. M., Tanaka, S., Chung, Y., Liu, T., Robertson, E. J., Lin, X., Feng, X., & Dong, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.c110.155820 · Cited by 109
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
Rodon, J. A., Carducci, M. A., Sepúlveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0192-4 · Cited by 108
Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
Kovacs, R. J., Maldonado, G., Azaro, A., Fernández, M. S., Romero, F. L., Sepulveda-Sánchez, J. M., Corretti, M., Carducci, M., Dolan, M., Gueorguieva, I., et al. (2015) · Cardiovascular Toxicology · doi:10.1007/s12012-014-9297-4 · Cited by 108
T Cell Receptor-Regulated TGF-β Type I Receptor Expression Determines T Cell Quiescence and Activation
Tu, E., Chia, C., Chen, W., Zhang, D., Park, S. A., Jin, W., Wang, D., Alegre, M., Zhang, Y. E., Sun, L., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.025 · Cited by 108
TGF‐β–responsive CAR‐T cells promote anti‐tumor immune function
Hou, A. J., Chang, Z. L., Lorenzini, M. H., Zah, E., & Chen, Y. Y. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10097 · Cited by 106
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors
Tolcher, A. W., Berlin, J. D., Cosaert, J., Kauh, J., Chan, E., Piha-Paul, S. A., Amaya, A., Tang, S., Driscoll, K., Kimbung, R., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3245-5 · Cited by 105
Tumour‐derived prostaglandin E2and transforming growth factor‐β synergize to inhibit plasmacytoid dendritic cell‐derived interferon‐α
Bekeredjian‐Ding, I., Schäfer, M., Hartmann, E., Pries, R., Parčina, M., Schneider, P., Giese, T., Endres, S., Wollenberg, B., & Hartmann, G. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03134.x · Cited by 104
MicroRNAs, TGF-β signaling, and the inflammatory microenvironment in cancer
Guo, L., Zhang, Y., Zhang, L., Huang, F., Li, J., & Wang, S. (2015) · Tumor Biology · doi:10.1007/s13277-015-4374-2 · Cited by 104
Ly6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance
AlHossiny, M., Luo, L., Frazier, W. R., Steiner, N., Gusev, Y., Kallakury, B., Glasgow, E. F., Creswell, K. M., Madhavan, S., Kumar, R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2654 · Cited by 104
A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys
Mitra, M. S., Lancaster, K., Adedeji, A. O., Palanisamy, G. S., Dave, R. A., Zhong, F., Holdren, M. S., Turley, S. J., Liang, W., Wu, Y., et al. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa024 · Cited by 104
p21 Cip1 and p27 Kip1 Act in Synergy to Alter the Sensitivity of Naive T Cells to TGF-β-Mediated G1 Arrest through Modulation of IL-2 Responsiveness
Wolfraim, L. A., Walz, T. M., James, Z., Fernandez, T., & Letterio, J. J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3093 · Cited by 102
TGF-β Signalling Is Required for CD4+ T Cell Homeostasis But Dispensable for Regulatory T Cell Function
Śledzińska, A., Hemmers, S., Mair, F., Gorka, O., Ruland, J., Fairbairn, L., Nissler, A., Müller, W., Waisman, A., Becher, B., et al. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001674 · Cited by 102
The Antisense Oligonucleotide Trabedersen (AP 12009) for the Targeted Inhibition of TGF-β2
Jaschinski, F., Rothhammer-Hampl, T., Jachimczak, P., Seitz, C. M., Schneider, A., & Schlingensiepen, K. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111798808266 · Cited by 102
Postnatal Deletion of the Type II Transforming Growth Factor-β Receptor in Smooth Muscle Cells Causes Severe Aortopathy in Mice
Hu, J. H., Hao, W., Jaffe, M., Airhart, N., Du, L., Angelov, S. N., Yan, J., Allen, J. K., Kang, I., Wight, T. N., et al. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306573 · Cited by 99
Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma
Ghisoli, M. L., Barve, M. A., Mennel, R. G., Lenarsky, C., Horvath, S., Wallraven, G., Pappen, B. O., Whiting, S. H., Rao, D., Senzer, N. N., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.86 · Cited by 98
The role of TGF-beta signaling in dendritic cell tolerance
Esebanmen, G. E., & Langridge, W. H. R. (2017) · Immunologic Research · doi:10.1007/s12026-017-8944-9 · Cited by 98
TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
Rodriguez-Ruiz, M. E., Rodríguez, I., Mayorga, L., Labiano, T., Barbés, B., Etxeberría, I., Ponz‐Sarvisé, M., Azpilikueta, A., Bolaños, E., Sanmamed, M. F., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0558 · Cited by 95
Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia
Dovey, O. M., Cooper, J. L., Mupo, A., Grove, C. S., Lynn, C., Conte, N., Andrews, R., Pacharne, S., Tzelepis, K., Vijayabaskar, M. S., et al. (2017) · Blood · doi:10.1182/blood-2017-01-760595 · Cited by 94
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
Cho, B. C., Daste, A., Ravaud, A., Salas, S., Isambert, N., McClay, E. F., Awada, A. H., Borel, C., Ojalvo, L. S., Helwig, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000664 · Cited by 93
Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment
Gonzàlez-Juncà, A., Driscoll, K. E., Pellicciotta, I., Du, S., Lo, C. H., Roy, R., Parry, R., Tenvooren, I., Marquez, D. M., Spitzer, M. H., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0310 · Cited by 91
Dual TGF‐β and PD‐1 blockade synergistically enhances MAGE‐A3‐specific CD8+ T cell response in esophageal squamous cell carcinoma
Chen, X., Wang, L., Li, P., Song, M., Qin, G., Gao, Q., Zhang, Z., Yue, D., Wang, D., Nan, S., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31730 · Cited by 90
Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy
Terabe, M., Robertson, F. C., Clark, K. T., Ravin, E. D., Bloom, A. C., Venzon, D. J., Kato, S., Mirza, A. M., & Berzofsky, J. A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1308616 · Cited by 89
A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo
Eberlein, C. A., Kendrew, J., McDaid, K., Alfred, A., Kang, J., Jacobs, V. N., Ross, S. J., Rooney, C., Smith, N. R., Rinkenberger, J. L., et al. (2012) · Oncogene · doi:10.1038/onc.2012.460 · Cited by 87
Targeting TGFβR2‐mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer
Huang, H., Zhang, Y., Gallegos, V., Sorrelle, N., Zaid, M. M., Toombs, J., Du, W., Wright, S., Hagopian, M., Wang, Z., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910515 · Cited by 87
Determination of TGFβ1 protein level in human primary breast cancers and its relationship with survival
Desruisseau, S., Palmari, J., Giusti, C., Romain, S., Martin, P.-M., & Berthois, Y. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602920 · Cited by 86
Smad4 deficiency in T cells leads to the Th17-associated development of premalignant gastroduodenal lesions in mice
Hahn, J. N., Falck, V., & Jirik, F. R. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45114 · Cited by 81
Tumor-Derived TGFβ Alters the Ability of Plasmacytoid Dendritic Cells to Respond to Innate Immune Signaling
Terra, M. L., Oberkampf, M., Fayolle, C., Rosenbaum, P., Guillerey, C., Dadaglio, G., & Leclerc, C. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2719 · Cited by 81
Deletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic properties
Novitskiy, S. V., Pickup, M. W., Chytil, A., Polosukhina, D., Owens, P., & Moses, H. L. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.1211639 · Cited by 79
Targeting latency-associated peptide promotes antitumor immunity
Gabriely, G., da Cunha, A. P., Rezende, R. M., Kenyon, B. M., Madi, A., Vandeventer, T., Skillin, N. P., Rubino, S. J., Garo, L. P., Mazzola, M. A., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aaj1738 · Cited by 79
Eosinophils are the major source of transforming growth factor-beta 1 in nodular sclerosing Hodgkin's disease.
Kadin, M. E., Butmarc, J. R., Elovic, A., & Wong, D. T. (1993) · PubMed Central · Cited by 77
Inflammation-Mediated Genetic and Epigenetic Alterations Drive Cancer Development in the Neighboring Epithelium upon Stromal Abrogation of TGF-β Signaling
Achyut, B. R., Bader, D. A., Robles, A. I., Wangsa, D., Harris, C. C., Ried, T., & Yang, H. H. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003251 · Cited by 77
Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade
Malenica, I., Adam, J., Corgnac, S., Mezquita, L., Auclin, É., Damei, I., Grynszpan, L., Gros, G., de Montpréville, V., Planchard, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25322-y · Cited by 77
Chemotactic Response Toward Chemokines and Its Regulation by Transforming Growth Factor-β1 of Murine Bone Marrow Hematopoietic Progenitor Cell-Derived Different Subset of Dendritic Cells
Ogata, M., Zhang, Y., Wang, Y., Itakura, M., Zhang, Y.-Y., Harada, A., Hashimoto, S.-I., & Matsushima, K. (1999) · Blood · doi:10.1182/blood.v93.10.3225.410k25_3225_3232 · Cited by 76
Migration of Cytotoxic T Lymphocytes in 3D Collagen Matrices
Sadjadi, Z., Zhao, R., Hoth, M., Qu, B., & Rieger, H. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.10.020 · Cited by 73
Activin receptor‐like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes
Yoon, J., Jung, S. M., Park, S. H., Kato, M., Yamashita, T., Lee, I., Sudo, K., Nakae, S., Han, J. S., Kim, O., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302524 · Cited by 73
First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Pfeiffer, N., Voykov, B., Renieri, G., Bell, K. C., Richter, P., Weigel, M., Thieme, H., Wilhelm, B., Lorenz, K., Feindor, M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188899 · Cited by 70
Integrin αvβ8 on T cells is responsible for suppression of anti-tumor immunity in multiple syngeneic models and is a promising target for tumor immunotherapy
Dodagatta-Marri, E., Ma, H.-Y., Liang, B., Li, J., Meyer, D. S., Sun, K.-H., Ren, X., Zivak, B., Rosenblum, M. D., Headley, M. B., et al. (2020) · doi:10.1101/2020.05.14.084913 · Cited by 70
T Cells Expressing Constitutively Active Akt Resist Multiple Tumor-associated Inhibitory Mechanisms
Sun, J., Dotti, G., Huye, L. E., Foster, A. E., Savoldo, B., Gramatges, M. M., Spencer, D. M., & Rooney, C. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.185 · Cited by 68
Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses
Groeneveldt, C., van Hall, T., van der Burg, S. H., ten Dijke, P., & van Montfoort, N. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.003 · Cited by 68
Inhibition of dendritic cell migration by transforming growth factor-β1 increases tumor-draining lymph node metastasis
Imai, K., Minamiya, Y., Koyota, S., Ito, M., Saito, H., Sato, Y., Motoyama, S., Sugiyama, T., & Ogawa, J. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-3 · Cited by 66
Targeted calcium influx boosts cytotoxic T lymphocyte function in the tumour microenvironment
Kim, K., Bae, S., Capece, T., Nedelkovska, H., de Rubio, R. G., Smrcka, A. V., Jun, C.-D., Jung, W., Park, B., Kim, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms15365 · Cited by 63
Smad4 Promotes Differentiation of Effector and Circulating Memory CD8 T Cells but Is Dispensable for Tissue-Resident Memory CD8 T Cells
Hu, Y., Lee, Y., Kaech, S. M., Garvy, B. A., & Cauley, L. S. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402369 · Cited by 60
Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma
Seystahl, K., Papachristodoulou, A., Burghardt, I., Schneider, H., Hasenbach, K., Janicot, M., Roth, P., & Weller, M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0465 · Cited by 60
Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing Immunosurveillance
Nakanishi, Y., Durán, Á., L’Hermitte, A., Shelton, P. M., Nakanishi, N., Reina‐Campos, M., Huang, J., Soldevila, F., Baaten, B. J. G., Tauriello, D. V. F., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.013 · Cited by 59
Self-citation
Infiltration of tumor‐associated macrophages is involved in tumor programmed death‐ligand 1 expression in early lung adenocarcinoma
Shima, T., Shimoda, M., Shigenobu, T., Ohtsuka, T., Nishimura, T., Emoto, K., Hayashi, Y., Iwasaki, T., Abe, T., Asamura, H., et al. (2019) · Cancer Science · doi:10.1111/cas.14272 · Cited by 58
Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade
Greco, R., Qu, H., Qu, H., Theilhaber, J., Shapiro, G., Gregory, R. C., Winter, C. G., Malkova, N. V., Sun, F. F., Jaworski, J. A., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1811605 · Cited by 58
Erratum To: Activin receptor‐like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes
Yoon, J., Jung, S. M., Park, S. H., Kato, M., Yamashita, T., Lee, I., Sudo, K., Nakae, S., Han, J. S., Kim, O., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201470040 · Cited by 57
Structure, sequence, and polymorphism of the Lyt-2 T cell differentiation antigen gene.
Liaw, C. W., Zamoyska, R., & Parnes, J. R. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.137.3.1037 · Cited by 52
Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells
Conroy, H., Galvin, K. C., Higgins, S. C., & Mills, K. H. G. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1188-y · Cited by 52
Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas
Papachristodoulou, A., Silginer, M., Weller, M., Schneider, H., Hasenbach, K., Janicot, M., & Roth, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3024 · Cited by 52
Summary of bi-shRNAfurin/GM-CSF Augmented Autologous Tumor Cell Immunotherapy (FANG™) in Advanced Cancer of the Liver
Nemunaitis, J. J., Barve, M. A., Orr, D. W., Kuhn, J. A., Magee, M., Lamont, J., Bedell, C., Wallraven, G., Pappen, B. O., Roth, A., et al. (2014) · Oncology · doi:10.1159/000360993 · Cited by 49
Resistance to TGFβ suppression and improved anti-tumor responses in CD8+ T cells lacking PTPN22
Brownlie, R. J., Garcia, C., Ravasz, M., Zehn, D., Salmond, R. J., & Zamoyska, R. (2017) · Nature Communications · doi:10.1038/s41467-017-01427-1 · Cited by 48
Obstacles to T cell migration in the tumor microenvironment
Nicolás‐Boluda, A., & Donnadieu, E. (2018) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2018.12.006 · Cited by 45
Immunotherapy for Human Renal Cell Carcinoma by Adoptive Transfer of Autologous Transforming Growth Factor β–Insensitive CD8+ T Cells
Wang, L., Wen, W., Yuan, J., Helfand, B. T., Yu, L., Shi, C., Tian, F., Zheng, J., Wang, F., Chen, L. V., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1758 · Cited by 44
Effects of GTP on Ca2+ movements across endoplasmic reticulum membranes
Dawson, A. P., & COMERFORD, J. G. (1989) · Cell Calcium · doi:10.1016/0143-4160(89)90060-2 · Cited by 43
A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer
COHN, A., LAHN, M. M., WILLIAMS, K. E., CLEVERLY, A. L., PITOU, C., KADAM, S. K., FARMEN, M. W., DESAIAH, D., RAJU, R., CONKLING, P., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2679 · Cited by 43
Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms
Bedinger, D., Lao, L., Khan, S., Lee, S., Takeuchi, T., & Mirza, A. M. (2016) · mAbs · doi:10.1080/19420862.2015.1115166 · Cited by 42
TGF-β induces HLA-G expression through inhibiting miR-152 in gastric cancer cells
Guan, Z., Song, B., Liu, F., Sun, D., Wang, K., & Qu, H. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-015-0177-4 · Cited by 40
A TGFβ-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repair–Deficient/Microsatellite Instability-High Colorectal Cancer
Endo, E., Okayama, H., Saito, K., Nakajima, S., Yamada, L., Ujiie, D., Kase, K., Fujita, S., Endo, H., Sakamoto, W., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0308 · Cited by 40
Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors.
Keedy, V. L., Bauer, T. M., Clarke, J. M., Hurwitz, H. I., Baek, I., Ha, I., Ock, C., Nam, S. Y., Kim, M., Park, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3031 · Cited by 35
Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 Receptors
Spender, L. C., Ferguson, G. J., Hughes, G. D., Davies, B. R., Goldberg, F. W., Herrera, B. M., Taylor, R. G., Strathearn, L. S., Sansom, O. J., Barry, S. T., et al. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.112946 · Cited by 32
Hitting More Birds with a Stone: Impact of TGF-β on ILC Activity in Cancer
Fionda, C., Stabile, H., Cerboni, C., Soriani, A., Gismondi, A., Cippitelli, M., & Santoni, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010143 · Cited by 31
Combinatorial Immunotherapies for Metastatic Colorectal Cancer
Janssen, E., Subtil, B., Ortiz, F. D. L. J., Verheul, H. M. W., & Tauriello, D. V. F. (2020) · Cancers · doi:10.3390/cancers12071875 · Cited by 31
Self-citation
Abstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor
Pei, H., Parthasarathy, S., Joseph, S. P., McMillen, W. T., Xu, X., Castaneda, S., Inigo, I. V., Britt, K. S., Anderson, B. D., Zhao, G., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-955 · Cited by 30
Chimeric antigen receptors designed to overcome transforming growth factor‐β‐mediated repression in the adoptive T‐cell therapy of solid tumors
Hartley, J., & Abken, H. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1064 · Cited by 30
An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages
Huber‐Ruano, I., Raventos, C. X., Cuartas, I., Sánchez-Jaro, C., Arias, A., Parra, J.-L., Wosikowski, K., Janicot, M., & Seoane, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx314 · Cited by 29
Regulation of Transforming Growth Factor-β-dependent Cyclooxygenase-2 Expression in Fibroblasts
Matsumura, T., Suzuki, T., Aizawa, K., Sawaki, D., Munemasa, Y., Ishida, J., & Nagai, R. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.014639 · Cited by 28
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia
Lin, C., Doi, T., Muro, K., Hou, M., Esaki, T., Hara, H., Chung, H. C., Helwig, C., Dussault, I., Osada, M., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00810-9 · Cited by 28
TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism
Canè, S., Snick, J. V., Uyttenhove, C., Pilotte, L., & den Eynde, B. J. V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001798 · Cited by 24
Deletion of GARP on mouse regulatory T cells is not sufficient to inhibit the growth of transplanted tumors
Vermeersch, E., Liénart, S., Collignon, A., Lucas, S., Gallimore, A., Gysemans, C. A., Unutmaz, D., Vanhoorelbeke, K., Meyer, S. F. D., Maes, W., et al. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.07.011 · Cited by 15
Controlled Stimulation of Magnetospheric Electrons by Radio Waves: Experimental Model for Lightning Effects
Goldberg, R. A., Curtis, S. A., Barcus, J. R., Siefring, C. L., & Kelley, M. C. (1983) · Science · doi:10.1126/science.219.4590.1324 · Cited by 12
Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma
Barve, M. A., Kuhn, J. A., Lamont, J., Beitsch, P. D., Manning, L., Pappen, B. O., Kumar, P., Wallraven, G., Senzer, N. N., & Nemunaitis, J. J. (2016) · Biomedical Genetics and Genomics · doi:10.15761/bgg.1000116 · Cited by 12
Abstract 3072: GFH018, a novel TGF-βRI inhibitor, for the treatment of advanced solid tumors
Hu, G., Zhao, R., Zhou, F., Lan, J., Zheng, B., Lü, Q., Lu, J., Wu, L., Sun, F., Hu, L., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-3072 · Cited by 11
P856 AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: results of a phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients
Yap, T. A., Araújo, D. V., Wood, D. L., Denis, J.-F., Gruosso, T., Tremblay, G., O'Connor‐McCourt, M. D., Ghosh, R., Sinclair, S., Nadler, P. I., et al. (2020) · Poster presentations · doi:10.1136/lba2019.10 · Cited by 9
Intradiscal Injection of YH14618, a First-in-Class Disease-Modifying Therapy, Reduces Pain and Improves Daily Activity in Patients with Symptomatic Lumbar Degenerative Disc Disease
Kwon, Y.-J., Kim, E. S., Kim, S.-M., Park, H., Byun, H. M., & Nam, S.-Y. (2015) · The Spine Journal · doi:10.1016/j.spinee.2015.07.093 · Cited by 7
Abstract 4688: AVID200: a novel computationally-designed TGF beta trap promoting anti-tumor T cell activity
O'Connor‐McCourt, M. D., Lenferink, A. E. G., Zwaagstra, J. C., Sulea, T. I., Collins, C., Singh, R., Durocher, Y., Cantin, C., & Koropatnick, J. D. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-4688 · Cited by 7
A Novel TGF-β2/Interleukin Receptor Signal Conversion Platform That Protects CAR/TCR T Cells from TGF-β2-Mediated Immune Suppression and Induces T Cell Supportive Signaling Networks
Boyerinas, B., Miller, S. M., Murray, R. C., Evans, J., Parsons, G., Seidl, K. J., Friedman, K. M., & Morgan, R. A. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.1911.1911 · Cited by 5
HTLV-III infection
Pien, F. D. (1986) · Postgraduate Medicine · doi:10.1080/00325481.1986.11699540 · Cited by 4
Integrin αvβ8 on T Cells is Responsible for Suppression of Anti-Tumor Immunity in Syngeneic Models and is a Promising Target for Tumor ImmunotherapyPreprint
Dodagatta-Marri, E., Ma, H., Liang, B., Li, J., Meyer, D. S., Sun, K.-H., Ren, X., Zivak, B., Rosenblum, M. D., Headley, M. B., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3588885 · Cited by 2
[Informativeness of various risk factors with regard to different forms of ischemic heart disease (epidemiologic study)].
Shalnova, S. A., & Деев, А. Д. (1982) · PubMed · Cited by 1
Abstract 4568: A novel TGF-beta receptor I kinase inhibitor demonstrated to be an effective immuno-therapy for cancer
Xu, Z., Lou, Y., Chen, L., Zeng, K., Sun, Q., Qu, Y., Wang, W., Wu, X., Ge, X., Gu, Y., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-4568 · Cited by 1

Sorted by citations

Mitochondrial dynamics in health and disease: mechanisms and potential targets
Chen, W., Zhao, H., & Li, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01547-9 · Cited by 1,306
The cancer-immunity cycle: Indication, genotype, and immunotype
Mellman, I., Chen, D. S., Powles, T. B., & Turley, S. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.011 · Cited by 1,018
TGF-β signaling in health and disease
Massagué, J., & Sheppard, D. (2023) · Cell · doi:10.1016/j.cell.2023.07.036 · Cited by 890
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A.-T., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 630
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 454

See all 379

Authors: Tauriello, D. V. F., Sancho, E., & Batlle, E.
Affiliations: Radboud University Medical Center (NL)
Institute for Research in Biomedicine (ES)
Institució Catalana de Recerca i Estudis Avançats (ES)
Corresponding author: Tauriello, Daniele V. F.
Batlle, Eduard
ORCID: Tauriello, Daniele V. F.
Sancho, Elena
Batlle, Eduard
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2021-10-20
Volume: 22
Issue: 1
Pages: 25-44
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/s41568-021-00413-6
OpenAlex: W3206061095
Cited by: 377
References: 320
Citations by year: 2026: 65 · 2025: 101 · 2024: 93 · 2023: 61 · 2022: 55 · 2021: 2
FWCI: 5.58
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
Radboud Repository (Radboud University) (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: TGF-beta signaling, tumor immune microenvironment, immune evasion, cancer-associated fibroblasts, innate immune suppression, TGF-beta inhibition, cancer immunotherapy, immune checkpoint blockade
MeSH terms: Humans, Immunotherapy, Neoplasms, Transforming Growth Factor beta, Immune Evasion, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Overcoming TGFβ-mediated immune evasion in cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks